Poultry Drugs MarketSize, Share & Industry Analysis, 2026-2034By TypeBy ApplicationBy Route of AdministrationBy Farm/end-user TypeBy Distribution Channel

Poultry drugs are the therapeutic and preventive pharmaceutical products used to treat and protect commercially and independently raised chickens, turkeys, ducks and geese, including antibiotics, parasiticides and anti-inflammatory formulations delivered through feed, water, injection or topical application. Buyers range from large integrated broiler and layer operations sourcing through veterinary and procurement channels to smallholder and backyard flock keepers purchasing through retail and informal distribution. The category sits within animal health rather than human pharmaceuticals, and its formulations are built around flock-level dosing rather than individual-bird treatment.

USD 8.15 billion of revenue was recorded in the global poultry drugs poultry drugs market in 2025. By 2034 the figure reaches USD 16.09 billion, a compound annual growth rate of 8.02% through the forecast period, along a series that runs USD 6.24 billion in 2020, USD 7.79 billion in 2024, USD 8.68 billion in 2026 and USD 11.69 billion in 2030.

The type mix shifts over the period. Antibiotics is the largest line in 2025 at USD 3.42 billion, a 42% share, moving to USD 5.79 billion and 36% by 2034. Parasiticides grows fastest at 9.49%, taking its share from 38% to 43%, while Antibiotics grows slowest at 6.16%. Parasiticides and Anti-inflammatory Drugs take share over the period; Antibiotics give it up while still growing in absolute terms.

The application split puts Chicken first, at USD 6.36 billion and 78% of revenue in 2025, rising to USD 12.23 billion and 76% in 2034. Duck grows faster at 10.6% against 7.54%, moving from 8% of revenue to 10% by 2034. It cuts the same total as the type axis from a different commercial angle, so revenue does not add across the two.

Asia Pacific is the largest region at 34% of 2025 revenue, worth USD 2.77 billion and reaching USD 6.11 billion by 2034. North America follows at 24%, moving from USD 1.96 billion to USD 3.38 billion, and Middle East and Africa is the smallest at 7%. Because Asia Pacific and Latin America take share, the revenue added by 2034 concentrates instead of spreading across all five regions.

Behind these figures sit five regions, three type lines and five segmentation axes, each reported for every year from 2020 to 2034. The headline 2025 value is a triangulation of published figures and category proxies, short of a directly sourced total, and the same applies to the segment, regional and country breakdowns drawn from it.

• A forecast-period rate of 8.02% takes the market from USD 8.15 billion in 2025 to USD 16.09 billion in 2034, against 5.49% recorded over the 2020-2025 historical period.
• The largest line by type is Antibiotics, worth USD 3.42 billion and 42% of revenue in 2025, rising to USD 5.79 billion and 36% by 2034.
• At 9.49%, Parasiticides grows faster than any other type line, moving from USD 3.1 billion and 38% of revenue in 2025 to USD 6.92 billion and 43% in 2034.
• The bull case puts 2034 revenue at USD 18.34 billion and the bear case at USD 14.56 billion, either side of the USD 16.09 billion base case, each with its own stated assumption in the full report.
• The largest region is Asia Pacific, generating USD 2.77 billion in 2025 (34% of the global total) and USD 6.11 billion by 2034, ahead of North America at 24%.
• China accounts for 40% of Asia Pacific in the base year, worth USD 1.11 billion in 2025 and reaching USD 2.44 billion by 2034, the worked country example carried through that region's chapters.
• Every line on all five segmentation axes and in each of the five regions carries its own revenue, share and growth rate for all fifteen years, 2020 through 2034, on a 2025 base.

Three movements define the forecast period in the global poultry drugs poultry drugs market: how the type mix changes, where regional weight shifts, and the rate at which the total compounds.

Not one of them points downward. Growth is everywhere in absolute terms, and the interest is entirely in where it lands.

Parasiticides grows faster than Antibiotics. 9.49% against 6.16%: that gap, between Parasiticides and Antibiotics, is the largest on the type axis. Parasiticides takes its share of revenue from 38% to 43% while Antibiotics gives up ground, from 42% to 36%. In absolute terms Parasiticides rises from USD 3.1 billion to USD 6.92 billion, while Antibiotics rises from USD 3.42 billion to USD 5.79 billion. Both grow; the gap is wide enough to reshape the mix inside a single forecast window.

Growth concentrates in Asia Pacific and Latin America. Asia Pacific moves from 34% of revenue in 2025 to 38% in 2034, worth USD 2.77 billion rising to USD 6.11 billion; Latin America moves from 15% of revenue in 2025 to 17% in 2034, worth USD 1.22 billion rising to USD 2.74 billion. The offsetting side is North America at 24% moving to 21%, Europe at 20% moving to 17%, Middle East and Africa at 7% moving to 7%, none of which contracts. Revenue added in this market is therefore concentrating geographically instead of spreading evenly, and a participant weighted toward a share-losing region grows more slowly than the market even while its own revenue climbs.

A continuation, not an inflection. Year by year the total runs USD 6.24 billion in 2020, USD 7.79 billion in 2024, USD 8.15 billion in 2025, USD 8.68 billion in 2026, USD 11.69 billion in 2030 and USD 16.09 billion in 2034. Against 5.49% through the historical period, the 8.02% forecast rate is a continuation; no year in the series interrupts it. A plan built on this market is therefore a plan about capturing a share of steady expansion, which is decided on the type and regional axes, not by the headline rate.

Parasiticides adds the most incremental growth

The 8.02% forecast rate rests on three things that can be measured separately: the size of the existing base, the mix shift on the type axis, and where regional growth is concentrated.

Downside case: USD 14.56 billion by 2034, against USD 16.09 billion in the base case

Upside case: USD 18.34 billion by 2034

Revenue is concentrated in Antibiotics

USD 1.96 billion of 2025 revenue is generated in North America, 24% of the global poultry drugs poultry drugs market rising to USD 3.38 billion in 2034. That makes it the second-largest region covered, in 2025 and again in 2034.

21% of global revenue sits here in 2034, below the 2025 level, a shift in share, not in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.

Antibiotics leads here as it does globally, at 42% of 2025 revenue, and Parasiticides again grows fastest at 9.49%. North America is reported axis by axis and country by country in the full study.

80% of North America's base-year revenue comes from the United States; USD 1.57 billion, rising to USD 2.7 billion by 2034. At 80% of regional revenue in the base year it is not one market among several, the region's trajectory is largely this country's trajectory. The region itself runs USD 1.96 billion to USD 3.38 billion over the same period, and this is the market carrying the country-level detail in the full report.

Composition here matches the global split: the largest line is Antibiotics at 42% of 2025 revenue, easing to 36% by 2034, and the fastest is Parasiticides at 9.49%, from 38% to 43%. Its 80% weight in North America means those movements carry straight into the regional totals. The full report reports the United States by type separately.

Poultry drugs fall under the Food and Drug Administration's Center for Veterinary Medicine, which classifies each product as either an over-the-counter drug, a prescription drug, or a veterinary feed directive item depending on its intended use and risk of resistance. A supplier must secure a New Animal Drug Application approval before marketing, demonstrating safety for the birds, safety of resulting food products for human consumption, and manufacturing consistency under current good manufacturing practice. Labeling must state approved indications, withdrawal periods before slaughter, and dosage instructions, and any drug delivered through feed requires coordination with a licensed veterinarian under the feed directive framework. The Department of Agriculture separately oversees claims tied to food safety inspection where applicable.

Competition in the United States runs between the suppliers this study tracks: Zoetis, Merck, Virbac, Boehringer Ingelheim, Elanco, Bayer Animal Health, Phibro Animal Health, Zydus and Ceva. Volume sits in Antibiotics at 42% of 2025 revenue; movement sits in Parasiticides at 9.49% growth. Country-level shares and positioning per company sit in the full report.

4.8% of global revenue is generated in Canada; USD 0.39 billion in 2025, reaching USD 0.68 billion in 2034, and 20% of North America.

20% of the global poultry drugs poultry drugs market sits in Europe in 2025, worth USD 1.63 billion on the way to USD 2.74 billion by 2034. That makes it the third-largest region covered, in 2025 and again in 2034.

17% of global revenue sits here in 2034, below the 2025 level, though revenue still rises throughout; the shift is in the region's weight against faster-growing ones, which is not the same as weakening demand.

Segment composition follows the global pattern: Antibiotics largest at 42% of 2025 revenue, Parasiticides fastest at 9.49%. The full report breaks Europe out along every axis and by country.

The largest single market in Europe is Poland, at USD 0.49 billion in 2025 and USD 0.82 billion in 2034. At 30% of the region in 2025 it leads, but a majority of Europe's revenue is generated in other markets. Set against USD 1.63 billion and USD 2.74 billion for the region, it is why this market, and not a smaller one, is the one reported in full.

Composition here matches the global split: the largest line is Antibiotics at 42% of 2025 revenue, easing to 36% by 2034, and the fastest is Parasiticides at 9.49%, from 38% to 43%. Its 30% weight in Europe means those movements carry straight into the regional totals. The full report reports Poland by type separately.

As a European Union member state, Poland regulates poultry drugs through the EU veterinary medicines framework, administered domestically by the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products working alongside the Chief Veterinary Inspectorate. A product must receive marketing authorization confirming efficacy, target-animal safety, and an established maximum residue limit before it can be sold, whether that authorization comes through a national procedure or a centralized route recognized across the bloc. Packaging and package leaflets must declare the withdrawal period, active substance, and approved species, and manufacturers must hold a manufacturing authorization demonstrating good manufacturing practice. Distribution of prescription-only veterinary medicines is restricted to licensed veterinarians and authorized wholesalers.

Competition in Poland runs between the suppliers this study tracks: Zoetis, Merck, Virbac, Boehringer Ingelheim, Elanco, Bayer Animal Health, Phibro Animal Health, Zydus and Ceva. Antibiotics, at 42% of 2025 revenue, is where the volume sits, and Parasiticides, growing at 9.49%, is where position changes hands over the forecast period. Weighting toward Europe means competing for 20% of 2025 global revenue, a base of USD 1.63 billion moving to USD 2.74 billion across the forecast period.

France is sized at USD 0.44 billion in 2025, rising to USD 0.74 billion by 2034; 5.4% of global revenue and 27% of Europe. It is reported separately from Poland across every segmentation axis in the full report.

Germany is sized at USD 0.39 billion in 2025, rising to USD 0.66 billion by 2034; 4.8% of global revenue and 24% of Europe. It is reported separately from Poland across every segmentation axis in the full report.

In Asia Pacific, 34% of global revenue puts 2025 at USD 2.77 billion with USD 6.11 billion projected for 2034. Among the five regions it ranks first by revenue in both years.

Share climbs to 38% by 2034, on growth above the market's own 8.02%, and with a bigger contribution to the revenue added over the period than the base-year figure suggests.

The type mix reported at global level applies here, with Antibiotics the largest line at 42% of 2025 revenue and Parasiticides the fastest-growing at 9.49%. The full report breaks Asia Pacific out along every axis and by country.

The largest single market in Asia Pacific is China, at USD 1.11 billion in 2025 and USD 2.44 billion in 2034. Its 40% of base-year regional revenue leads the region, though enough sits elsewhere that Asia Pacific is not a proxy for it. The region itself runs USD 2.77 billion to USD 6.11 billion over the same period, and this is the market carrying the country-level detail in the full report.

Demand in China follows the type mix reported at global level: Antibiotics is the largest line at 42% of 2025 revenue, moving to 36% by 2034, while Parasiticides grows fastest at 9.49% and takes its share from 38% to 43%. Its 40% weight in Asia Pacific means those movements carry straight into the regional totals. The full report reports China by type separately.

Poultry drugs in China are regulated by the Ministry of Agriculture and Rural Affairs, which administers the national veterinary drug licensing system and maintains the register of approved veterinary medicinal products. A supplier must obtain a veterinary drug production license and a corresponding product approval number confirming that the formulation meets national quality standards before it can be manufactured or sold domestically. Labeling must conform to the national veterinary drug labeling standard, disclosing composition, indicated species, dosage, and withdrawal period ahead of slaughter. Products intended for export or import additionally pass through customs quarantine inspection administered alongside the agriculture ministry, and antimicrobial classes face separate restriction lists aimed at curbing resistance in food-producing birds.

The suppliers tracked in this study (Zoetis, Merck, Virbac, Boehringer Ingelheim, Elanco, Bayer Animal Health, Phibro Animal Health, Zydus and Ceva) compete in China across the type lines above. Volume sits in Antibiotics at 42% of 2025 revenue; movement sits in Parasiticides at 9.49% growth. That makes Asia Pacific a 34% share of 2025 global revenue, USD 2.77 billion rising to USD 6.11 billion, for any supplier deciding where to concentrate.

7.5% of global revenue is generated in India; USD 0.61 billion in 2025, reaching USD 1.34 billion in 2034, and 22% of Asia Pacific.

Within Asia Pacific, Indonesia accounts for 15% of regional revenue and 5.2% of the global total, worth USD 0.42 billion in 2025 and USD 0.92 billion by 2034.

In Latin America, 15% of global revenue puts 2025 at USD 1.22 billion on the way to USD 2.74 billion by 2034. That makes it the fourth-largest region covered, in 2025 and again in 2034.

By 2034 the share has moved up to 17%, on growth above the market's own 8.02%, and with a bigger contribution to the revenue added over the period than the base-year figure suggests.

Within the region the type split tracks the global one; 42% of 2025 revenue in Antibiotics, fastest growth of 9.49% in Parasiticides. Per-axis and per-country detail for Latin America sits in the full report.

The largest single market in Latin America is Brazil, at USD 0.67 billion in 2025 and USD 1.51 billion in 2034. 55% of the region in the base year makes it the largest market here without making it the region. Set against USD 1.22 billion and USD 2.74 billion for the region, it is why this market, and not a smaller one, is the one reported in full.

Brazil buys along the same lines as the market globally; Antibiotics first at 42% of 2025 revenue and 36% in 2034, Parasiticides fastest at 9.49% on a share moving from 38% to 43%. Since 55% of Latin America's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. Revenue by type for Brazil is reported separately in the full report.

The Ministry of Agriculture, Livestock and Supply governs veterinary drugs for poultry through its Department of Inputs and Animal Health, which maintains the registration system every product must pass through before sale. Registration requires evidence of efficacy and target-species safety along with an established residue limit that determines the withdrawal interval producers must observe ahead of slaughter. Manufacturing sites must hold a sanitary license confirming compliance with good manufacturing practice, and labeling must state approved indications, dosage, and withdrawal timing in Portuguese. Brazil's large export-oriented poultry sector means residue standards are also shaped by the requirements of importing markets, and antimicrobials used for growth promotion face additional restriction under the ministry's ongoing resistance-control measures.

In Brazil the field is Zoetis, Merck, Virbac, Boehringer Ingelheim, Elanco, Bayer Animal Health, Phibro Animal Health, Zydus and Ceva. Volume sits in Antibiotics at 42% of 2025 revenue; movement sits in Parasiticides at 9.49% growth. That makes Latin America a 15% share of 2025 global revenue, USD 1.22 billion rising to USD 2.74 billion, for any supplier deciding where to concentrate.

Mexico is sized at USD 0.31 billion in 2025, rising to USD 0.69 billion by 2034; 3.8% of global revenue and 25% of Latin America. It is reported separately from Brazil across every segmentation axis in the full report.

In Middle East and Africa, 7% of global revenue puts 2025 at USD 0.57 billion and reaches USD 1.13 billion by 2034. It is a marginal region on this axis, fifth by revenue throughout the period.

Its share moves to 7% by 2034, a shift in share, not in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.

The type mix reported at global level applies here, with Antibiotics the largest line at 42% of 2025 revenue and Parasiticides the fastest-growing at 9.49%. The full report breaks Middle East and Africa out along every axis and by country.

Saudi Arabia is the largest market within Middle East and Africa, generating USD 0.2 billion in 2025 and projected to reach USD 0.4 billion by 2034. It accounts for 35% of regional revenue in the base year, the largest single share without dominating the region outright. Regional revenue of USD 0.57 billion in 2025 and USD 1.13 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

Composition here matches the global split: the largest line is Antibiotics at 42% of 2025 revenue, easing to 36% by 2034, and the fastest is Parasiticides at 9.49%, from 38% to 43%. With 35% of Middle East and Africa concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Saudi Arabia carries its own type breakdown in the full report.

Poultry drugs entering the Saudi market fall under the Saudi Food and Drug Authority, which registers veterinary medicinal products through its own dossier-based approval process before granting market authorization. A supplier must demonstrate product safety, efficacy, and quality, and manufacturing facilities are expected to conform to internationally recognized good manufacturing practice standards accepted by the authority. Labeling must appear in Arabic alongside English, stating approved indications, dosage, and the withdrawal period required before poultry products reach the food chain. As a member of the Gulf Cooperation Council, Saudi Arabia's requirements are also informed by harmonized Gulf standards covering veterinary drug registration and residue limits, and the Ministry of Environment, Water and Agriculture plays a coordinating role in enforcement at the farm level.

Competition in Saudi Arabia runs between the suppliers this study tracks: Zoetis, Merck, Virbac, Boehringer Ingelheim, Elanco, Bayer Animal Health, Phibro Animal Health, Zydus and Ceva. The commercially relevant division is 42% of 2025 revenue in Antibiotics, where the volume is, against 9.49% growth in Parasiticides, where share moves. Weighting toward Middle East and Africa means competing for 7% of 2025 global revenue, a base of USD 0.57 billion moving to USD 1.13 billion across the forecast period.

Within Middle East and Africa, South Africa accounts for 25% of regional revenue and 1.7% of the global total, worth USD 0.14 billion in 2025 and USD 0.28 billion by 2034.

Request this sample to see the full data tables and segment-level detail behind this analysis.

This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by Type, Application, Route of Administration, Farm/End-User Type, Distribution Channel, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.